Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension

Thorax

Volumn 52, Issue 12, 1997, Pages 1051-1055

  Kharitonov, Sergei A ^a   Cailes, Jeremy B ^a   Black, Carol M ^a   Du Bois, Roland M ^a   Barnes, Peter J ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Fibrosing alveolitis; Nitric oxide; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

NITRIC OXIDE;

ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOPPLER ECHOCARDIOGRAPHY; EXPIRED AIR; FIBROSING ALVEOLITIS; HUMAN; LUNG FUNCTION TEST; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLEROSIS; VASCULAR DISEASE;

EID: 0030714983     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.12.1051     Document Type: Article

References (55)

1. Ungerer RG, Tashkin DP, Furst D, Clements PJ, Gong H Jr, Bein M, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983;75:65-74.
2. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-24.
3. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82:139-148.
4. Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin". Arthritis Rheum 1991;34:1495-501.
5. Freemont AJ, Hoyland J, Fielding P, Hodson N, Jayson NU. Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalised microangiopathy. Br J Dermatol 1992;126:561-8.
6. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166: 255-63.
7. Matucci-Cerinic M, Pietrini U, Marabini S. Local venomotor response to intravenous infusion of substance P and glyceryl trinitrate in systemic sclerosis. Clin Exp Rheumatol 1990;8:561-5.
8. McCormack D. Endothelium-derived relaxing factors and the human pulmonary circulation. Lung 1990;168(Suppl): 35-42.
9. Dinh-Xuan AT. Endothelial modulation of pulmonary vascular tone. Eur Respir J 1992;5:757-62.
10. Gustafsson LE, Leone AM, Persson MG, Wiklund NP, Moncada S. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun 1991;181:852-7.
11. Borland CD, Cox Y, Higenbottam T. Measurement of exhaled nitric oxide in man. Thorax 1993;48:1160-2.
12. Barnes PJ, Beivisi MG. Nitric oxide and lung disease. Thorax 1993;48:1034-43.
13. Barnes PJ, Kharitonov SA. Exhaled nitric oxide: a new lung function test. Thorax 1996;51:233-7.
14. Giad A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21.
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23: 581-90.
16. Kharitonov SA, Logan-Sinclair RB, Busset CM, Shinebourne EA. Peak expiratory nitric oxide differences in men and women: relation to the menstrual cycle. Br Heart J 1994;72:243-5.
17. Kharitonov SA, Lalloo UG, Barnes PJ. Reference values of exhaled and nasal nitric oxide for women and men 20 to 85 years of age. Am J Respir Crit Care Med 1977;155: A825.
18. Brecker SJ, Xiao HB, Stojnic BB, Mbaissouroum M, Gibson DG. Assessment of the peak tricuspid regurgitant velocity from the dynamics of retrograde flow. Int J Cardiol 1992; 34:267-71.
19. Denison DM, Cramer DS, Hanson PJ. Lung function testing and AIDS. Respir Med 1989;83:133-8.
20. Spiro SG, Dowdeswell IR. Arterialised ear lobe blood samples for blood gas tensions. Br J Dis Chest 1976;70: 263-8.
21. Cotes JE, Chimi DJ, Quanjer PH, Roca J, Yemault JC. Standardisation of the measurement of transfer factor (diffusing capacity). Report Working Party Standardisation of Lung Function Tests, European Community for Steel and Coal. Official Statement of the ERS. Eur Respir J Suppl 1993;16:41-52.
22. Quanier PH, Tanimeling GJ, Cotes JE, Pedersen OF, Peslin R, Yemault JC. Lung volumes and forced ventilators flows. Report Working Party Standardisation of Lung Function Tests, European Community for Steel and Coal, Official Statement of the ERS. Eur Respir J Suppl 1993;16:5-40.
23. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343:133-5.
24. Norusis MJ. SPSS for windows. Base system users guide, release 6.0. Chicago: SPSS Inc, 1993:1-828.
25. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
26. Robbins RA, Barnes PJ, Springall DR, Warren JB, Kwon OJ, Buttery LDK, et al. Expression of inducible nitric oxide in human lung epithelial cells. Biochem Biophys Res Commun 1994;203:209-18.
27. Bernhardt J, Tschudi M, Dohi Y, Gut I, Urwyler B, Buhler FR, et al. Release of nitric oxide from human vascular smooth muscle cells. Biochem Biophys Res Commun 1991; 180:907-12.
28. Kharitonov SA, Chung FK, Evans DJ, O'Connor BJ, Barnes PJ. The elevated level of exhaled nitric oxide in asthmatic patients is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med 1996;153:1773-80.
29. Kharitonov SA, Barnes PJ. Nasal contribution to exhaled nitric oxide during exhalation against resistance or during breatholding. Thorax 1997;52:540-4.
30. Silver M, Miller KS, Kinselia MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990;88:470-6.
31. Saleh D, Barnes PJ, Giad A. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997;155:1763-9.
32. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87: 1620-1.
33. 2-induced lung injury in rats. Eur Respir J 1995;8:1115-21.
34. Last JA, Gelzeichter TR, Pinkerton KE, Walker RM, Witschi H. A new model of pulmonary fibrosis. Am Rev Respir Dis 1993;148:487-94.
35. Dinh-Xuan AT, Higenbottam TW, Clelland CA, Pepke-Zaba J, Cremona G, Butt AY, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991;324:1539-47.
36. Adnot S, Raffestin B, Eddahibi S, Braquet P, Chabrier PE. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest 1991;87:155-62.
37. Barer G, Emery C, Stewart A, Bee D, Howard P. Endothelial control of the pulmonary circulation in normal and chronically hypoxic rats. J Physiol Lond 1993;463:1-16.
38. Hampl V, Archer SL, Nelson DP, Weir EK. Chronic EDRF inhibition and hypoxia: effects on pulmonary circulation and systemic blood pressure. J Appl Physiol 1993;75: 1748-57.
39. Archer S, Hampl V, McKenzie Z, Nelson D, Huang J, Shultz PJ, et al. Role of endothelial derived nitric oxide in normal and hypertensive pulmonary vasculature. Semin Respir Crit Care Med 1994;15:179-87.
40. Winkelmann BR, Kullmer TH, Kneissi DG, Trenk D, Kronenberger H. Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. Chest 1994;105:1383-91.
41. Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostoni A. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 1992;1:1.
42. Harrison NK, McAnulty RJ, Haslam PL, Black CM, Laurent GJ. Evidence for protein oedema, neutrophil influx, and enhanced collagen production in lungs of patients with systemic sclerosis. Thorax 1990;45:606-10.
43. Drenk F, Deicher HR. Pathophysiological effects of endothelial cytotoxic activity derived from sera of patients with progressive systemic sclerosis. J Rheumatol 1988;15: 468-74.
44. Drenk F, Mensing H, Serbin A, Deicher H. Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int 1985;5:259-63.
45. Etoh T, Igarashi A, Iozunii K, Ishibashi Y, Takehara K. The effects of scleroderma sera on endothelial cell survival in vitro. Arch Dermatol Res 1990;282:516-9.
46. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993;92:99-104.
47. Radomski MW, Palmer RN, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;ii:1057-8.
48. Radomski MW, Vallance P, Whitley G, Foxwell N, Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res 1993;27:1380-2.
49. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992; 85:2284-90.
50. Barrett NI, Willis AL, Vane JW. Inhibition of platelet-derived nitrogen release by nitric oxide (EDRF). Agents Actions 1989;27:488-91.
51. Bath PM, Hassall DG, Gladwin AM, Paimer RM, Martin JF. Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb 1991;11:254-60.
52. Rubanyi GM, Ho EH, Cantor EH, Lumma WC, Botelho LH. Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leukocytes. Biochem Biophys Res Commun 1991;181:1392-7.
53. Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am J Med 1978;64:998-1004.
54. Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990;21:467-74.
55. Steen VD, Graham G, Conte C, Owens G, Medsgcr TA, Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992;35:765-70.